Autologous Bone Marrow Concentrate-Clinical Efficacy in the Treatment of Knee Osteoarthritis

February 10, 2020


Background: Knee osteoarthritis is a leading cause of pain and disability worldwide. Non-surgical treatment options are limited in their number and duration of pain relief. The potential for cellular based regenerative therapies to bridge the gap between shortterm symptomatic relief and total knee arthroplasty has received abundant attention in the past few years. Here we present pain and outcomes data on 254 patients with knee osteoarthritis treated with intra-articular bone marrow concentrate.

Purpose: Demonstrate the efficacy and safety of Bone Marrow Aspirate Concentrate in the treatment of osteoarthritis of the knee.

Study Design: Prospective Case Series.

Methods: Treatment registry data for 254 patients diagnosed with Kellgren-Lawrence Stage 2-4 knee osteoarthritis were analyzed. Data regarding adverse events, Visual Analog Pain Scale (VAS), and Western Ontario and McMaster Universities
Osteoarthritis Index metrics (WOMAC) were obtained at baseline, three months, six months, one year and two years.

Results: In this prospective case series adverse events were limited to transient pain and swelling of the treated joint. The mean reported WOMAC changes from pre-procedure to two years post-procedure were as follows: Pain + 21, Stiffness +22 and Function + 19. The mean reported VAS was reduced from 4.8 at baseline to 2.3 at two years.

Conclusion: This study of intra-articular injection of autologous bone marrow concentrate in patients diagnosed with knee
osteoarthritis demonstrates encouraging results for positive outcomes without complication. Further study with randomized
controlled trials is warranted to prove the potential of this intervention.